Onconetix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on September 20, 2024, regarding events occurring on September 19, 2024. Onconetix, Inc. (ONCO), an emerging growth company, entered into an Amended and Restated Forbearance Agreement with Veru Inc. This agreement modifies terms related to outstanding notes payable stemming from an asset purchase agreement originally executed in April 2023.
Key Financial Metrics and Debt Obligations
The filing details specific debt obligations and payment terms rather than standard operating financial metrics like revenue or net income.
- Outstanding Notes: The agreement covers the "April Veru Note" ($5.0 million principal) and the "September Veru Note" ($5.0 million principal).
- Interest Rates: Both notes now accrue interest at 10% per annum on unpaid principal balances. Interest on the April Note accrues from April 20, 2024; interest on the September Note accrues from October 1, 2024.
- Required Payments: The Company must make monthly payments equal to 25% of "Ordinary Cash Revenue" (increased from 15%). This includes cash receipts from Proteomedix licensing, Proclarix sales, and Labcorp milestones/royalties.
- Financing Proceeds: The Company must pay 20% of net proceeds from financing or non-ordinary course transactions (increased from 10%).
- Equity Conversion: Veru's 3,000 shares of Series A Preferred Stock will be converted to Common Stock following the Company's reverse stock split.
Material Changes Versus Prior Period
The Amended and Restated Forbearance Agreement introduces several material changes compared to the Original Forbearance Agreement filed in April 2024:
- Extension of Maturity: The due date for the September Veru Note is extended to June 30, 2025 (or earlier upon an Event of Default).
- Increased Revenue Share: The percentage of Ordinary Cash Revenue required to be paid to Veru increased from 15% to 25%, effective for cash receipts in September 2024.
- Increased Financing Share: The percentage of net proceeds from financing transactions payable to Veru increased from 10% to 20%, effective for proceeds received after September 19, 2024.
- Payment Priority: Required payments are applied first to accrued interest on the April Note, then to its principal. Once the April Note is fully repaid, payments apply to the September Note's interest and principal.
- Early Repayment Discount: If all principal and interest on both notes are repaid in cash by December 31, 2024, the principal balance of the September Note is reduced from $5.0 million to $3.5 million.
Guidance, Outlook, and Risks
The filing does not provide forward-looking financial guidance or management commentary on future revenue projections. However, it outlines significant contingencies and risks:
- Event of Default: The forbearance period for the April Note ends on March 31, 2025, or earlier if an Event of Default occurs. The September Note maturity is similarly subject to an Event of Default.
- Liquidity Constraints: The Company's ability to service debt is directly tied to its ability to generate cash receipts from specific product lines (Proteomedix, Proclarix) and milestone payments.
- Equity Dilution: The agreement allows for the September Note to be repaid in cash, common stock, or a combination, subject to mutual consent, which could impact share count.
Key Facts for Investor Verification
- Verify the Company's current cash position and ability to meet the increased 25% revenue share requirement starting October 2024.
- Confirm the status of the reverse stock split and the subsequent conversion of Veru's Series A Preferred Stock to Common Stock.
- Monitor the Company's ability to repay the notes by December 31, 2024, to secure the $1.5 million principal reduction on the September Note.
- Review the definition of "Event of Default" in the attached Exhibit 10.1 to understand triggers that could accelerate debt repayment.
- Assess the impact of the 10% interest accrual on the Company's future cash flow requirements.